Your browser doesn't support javascript.
loading
Sulfonium-Stapled Peptides-Based Neoantigen Delivery System for Personalized Tumor Immunotherapy and Prevention.
Zhang, Yaping; Jiang, Leying; Huang, Siyong; Lian, Chenshan; Liang, Huiting; Xing, Yun; Liu, Jianbo; Tian, Xiaojing; Liu, Zhihong; Wang, Rui; An, Yuhao; Lu, Fei; Pan, Youdong; Han, Wei; Li, Zigang; Yin, Feng.
Afiliación
  • Zhang Y; Pingshan Translational Medicine Center, Shenzhen Bay Laboratory, Shenzhen, 518055, P. R. China.
  • Jiang L; State Key Laboratory of Chemical Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, 518055, P. R. China.
  • Huang S; State Key Laboratory of Chemical Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, 518055, P. R. China.
  • Lian C; Pingshan Translational Medicine Center, Shenzhen Bay Laboratory, Shenzhen, 518055, P. R. China.
  • Liang H; Pingshan Translational Medicine Center, Shenzhen Bay Laboratory, Shenzhen, 518055, P. R. China.
  • Xing Y; Pingshan Translational Medicine Center, Shenzhen Bay Laboratory, Shenzhen, 518055, P. R. China.
  • Liu J; Pingshan Translational Medicine Center, Shenzhen Bay Laboratory, Shenzhen, 518055, P. R. China.
  • Tian X; State Key Laboratory of Chemical Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, 518055, P. R. China.
  • Liu Z; Pingshan Translational Medicine Center, Shenzhen Bay Laboratory, Shenzhen, 518055, P. R. China.
  • Wang R; Pingshan Translational Medicine Center, Shenzhen Bay Laboratory, Shenzhen, 518055, P. R. China.
  • An Y; Pingshan Translational Medicine Center, Shenzhen Bay Laboratory, Shenzhen, 518055, P. R. China.
  • Lu F; State Key Laboratory of Chemical Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, 518055, P. R. China.
  • Pan Y; NeoCura Bio-Medical Technology Co. Ltd., Shenzhen, 518055, P. R. China.
  • Han W; State Key Laboratory of Chemical Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, 518055, P. R. China.
  • Li Z; Pingshan Translational Medicine Center, Shenzhen Bay Laboratory, Shenzhen, 518055, P. R. China.
  • Yin F; State Key Laboratory of Chemical Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, 518055, P. R. China.
Adv Sci (Weinh) ; 11(24): e2307754, 2024 Jun.
Article en En | MEDLINE | ID: mdl-38605600
ABSTRACT
Neoantigen peptides hold great potential as vaccine candidates for tumor immunotherapy. However, due to the limitation of antigen cellular uptake and cross-presentation, the progress with neoantigen peptide-based vaccines has obviously lagged in clinical trials. Here, a stapling peptide-based nano-vaccine is developed, comprising a self-assembly nanoparticle driven by the nucleic acid adjuvant-antigen conjugate. This nano-vaccine stimulates a strong tumor-specific T cell response by activating antigen presentation and toll-like receptor signaling pathways. By markedly improving the efficiency of antigen/adjuvant co-delivery to the draining lymph nodes, the nano-vaccine leads to 100% tumor prevention for up to 11 months and without tumor recurrence, heralding the generation of long-term anti-tumor memory. Moreover, the injection of nano-vaccine with signal neoantigen eliminates the established MC-38 tumor (a cell line of murine carcinoma of the colon without exogenous OVA protein expression) in 40% of the mice by inducing potent cytotoxic T lymphocyte infiltration in the tumor microenvironment without substantial systemic toxicity. These findings represent that stapling peptide-based nano-vaccine may serve as a facile, general, and safe strategy to stimulate a strong anti-tumor immune response for the neoantigen peptide-based personalized tumor immunotherapy.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas contra el Cáncer / Medicina de Precisión / Inmunoterapia / Antígenos de Neoplasias Límite: Animals / Female / Humans Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas contra el Cáncer / Medicina de Precisión / Inmunoterapia / Antígenos de Neoplasias Límite: Animals / Female / Humans Idioma: En Año: 2024 Tipo del documento: Article